封面
市场调查报告书
商品编码
1588502

疫苗市场规模、份额、成长分析、按技术、按类型、按适应症、按管理途径、按最终用户、按地区 - 行业预测,2024-2031 年

Vaccines Market Size, Share, Growth Analysis, By Technology, By Type, By Disease Indication, By Route of Administration, By End User, By Region - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 212 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球疫苗市场规模将为720亿美元,从2023年的746.6亿美元成长到2031年的998.5亿美元,在预测期间(2024-2031年)预计复合年增长率为3.70%。

由于慢性病的流行和人们对医疗保健的兴趣日益浓厚,预计全球疫苗市场将显着增长。随着医疗技术的发展和创新疫苗研发投资的加大,市场参与者可能会遇到新的机会。在新的免疫计划和疫苗宣导活动的支持下,预防性医疗保健趋势预计将推动疫苗的使用。此外,疫苗接种活动和疫苗技术的进步可能会进一步增强市场参与企业未来几年的成长前景。然而,有关疫苗的广泛错误讯息、高昂的市场开拓成本和严格的监管要求等挑战可能会阻碍市场的进步。总体而言,疫苗市场可能会因全球健康挑战和意识的提高而扩大,但相关人员需要克服这些障碍才能利用新的商机。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 次要/一级资讯来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 价格分析
  • 技术分析
  • 价值链分析
  • 专利分析
  • 供应链分析
  • PESTEL分析
  • 总体经济指标
  • 案例研究分析
  • 客户和购买标准分析

疫苗市场:依技术分类

  • 市场概况
  • 结合疫苗
  • 重组疫苗
  • 惰性/次单位疫苗
  • 减毒活病毒疫苗
  • 类毒素疫苗
  • 病毒载体疫苗
  • mRNA疫苗
  • 其他疫苗

疫苗市场:按类型

  • 市场概况
  • 多效价疫苗
  • 单价疫苗

疫苗市场:依适应症分类

  • 市场概况
  • 肺炎链球菌感染
  • 流感
  • 联合疫苗
  • HPV
  • 病菌感染感染
  • 带状疱疹
  • 轮状病毒
  • MMR
  • 水痘
  • 肝炎
  • DTP
  • 脊髓灰质炎
  • RSV
  • 其他适用疾病

疫苗市场:依给药途径

  • 市场概况
  • 口服给药(PO)
  • 鼻内给药 (NAS)
  • 皮下途径(subcut)
  • 肌肉注射(IM)

疫苗市场:依最终用户分类

  • 市场概况
  • 成人疫苗
  • 儿科疫苗

疫苗市场:按地区

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位(2023年)
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率(2023年)

主要企业简介

  • GSK Plc(UK)
  • Merck & Co., Inc.(US)
  • Pfizer Inc.(US)
  • Sanofi(France)
  • CSL(Australia)
  • Emergent(US)
  • Johnson & Johnson Services, Inc.(US)
  • AstraZeneca(UK-Sweden)
  • Serum Institute of India Pvt., Ltd.(India)
  • Bavarian Nordic(Denmark)
  • Mitsubishi Tanabe Pharma Corporation(Japan)
  • Daiichi Sankyo Company, Limited(Japan)
  • Panacea Biotec(India)
  • Biological E Limited(India)
  • Bharat Biotech(India)
  • Novavax(US)
  • Inovio Pharmaceuticals(US)
  • Sinovac(China)
  • Incepta Pharmaceuticals Ltd.(Bangladesh)
  • Valneva SE(France)
  • VBI Vaccine Inc.(US)
  • Bio Farma(Indonesia)
  • Microgen(Russia)
  • ZHI FEI Biological(China)
  • Indian Immunologicals Limited(India)
简介目录
Product Code: SQMIG35H2262

Global Vaccines Market size was valued at USD 72 billion in 2022 and is poised to grow from USD 74.66 billion in 2023 to USD 99.85 billion by 2031, growing at a CAGR of 3.70% during the forecast period (2024-2031).

The global vaccines market is poised for substantial growth, driven by the increasing prevalence of chronic diseases and a heightened focus on healthcare. As medical technology evolves and investment in research and development of innovative vaccines intensifies, market players are likely to encounter new opportunities. The trend towards preventive healthcare is expected to foster greater vaccine adoption, supported by the introduction of new immunization programs and vaccine awareness initiatives. Furthermore, vaccination drives and advancements in vaccine technology will further enhance growth prospects for market participants over the forthcoming years. However, challenges such as widespread misinformation about vaccines, significant development costs, and strict regulatory requirements may hinder market progression. Overall, while the vaccines market is set to expand in response to global health challenges and growing awareness, stakeholders must navigate these obstacles to capitalize on the emerging opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccines Market Segmental Analysis

Global Vaccines Market is segmented by Technology, Type, Disease Indication, Route of Administration, End User, and region. Based on Technology, the market is segmented into Conjugate Vaccines, Recombinant Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Viral Vector Vaccines, MRNA Vaccines, and Other Vaccines. Based on Type, the market is segmented into Multivalent Vaccines, and Monovalent Vaccines. Based on Disease Indication, the market is segmented into Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, RSV, and Other Disease Indications. Based on Route of Administration, the market is segmented into Oral Route (PO), Intranasal Route (NAS), Subcutaneous Route (Subcut), Intramuscular Route (IM). Based on End User, the market is segmented into Adult Vaccines, and Pediatric Vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Vaccines Market

The surge in the incidence of infectious and chronic diseases globally has significantly heightened awareness regarding the importance of preventive healthcare, acting as a key market driver for the global vaccines market. As populations become more cognizant of the benefits associated with vaccination, the demand for effective and reliable vaccine solutions is set to rise. Vaccines not only help in thwarting the spread of diseases but also play a crucial role in alleviating healthcare burdens before they escalate into major health crises. Consequently, this increasing awareness and proactive health management are expected to catalyze substantial growth in vaccine sales across diverse demographics.

Restraints in the Global Vaccines Market

The Global Vaccines market faces a significant restraint due to the intricacies involved in vaccine development, which includes extensive clinical trials and comprehensive testing protocols. These processes are not only time-consuming but also entail substantial financial investments, leading to high development costs for vaccine manufacturers. Such economic burdens can deter smaller companies from entering the market or limit innovation, ultimately constraining the overall growth potential of the vaccines market. Additionally, the lengthy timelines required for regulatory approval further exacerbate the challenge, making it difficult for new vaccines to be introduced swiftly to address emerging health threats.

Market Trends of the Global Vaccines Market

The global vaccines market is experiencing a notable trend towards personalized vaccines, driven by the increasing demand for personalized medicine and advancements in healthcare technology. Companies are increasingly focusing on developing tailored vaccines that cater to individual patient profiles, thereby enhancing efficacy and improving overall health outcomes. This shift not only opens new avenues for vaccine providers but also aligns with evolving patient expectations for customized healthcare solutions. As the landscape of immunization evolves, the integration of personalized vaccination strategies is anticipated to revolutionize the market, presenting significant growth opportunities and fortifying the commitment to improved public health initiatives.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Pricing Analysis
  • Technology Analysis
  • Value Chain Analysis
  • Patent Analysis
  • Supply Chain Analysis
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Case Study Analysis
  • Customer & Buying Criteria Analysis

Vaccines Market by Technology

  • Market Overview
  • Conjugate Vaccines
  • Recombinant Vaccines
  • Inactivated & Subunit Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Viral Vector Vaccines
  • MRNA Vaccines
  • Other Vaccines

Vaccines Market by Type

  • Market Overview
  • Multivalent Vaccines
  • Monovalent Vaccines

Vaccines Market by Disease Indication

  • Market Overview
  • Pneumococcal Disease
  • Influenza
  • Combination Vaccines
  • HPV
  • Meningococcal Disease
  • Herpes Zoster
  • Rotavirus
  • MMR
  • Varicella
  • Hepatitis
  • DTP
  • Polio
  • RSV
  • Other Disease Indications

Vaccines Market by Route of Administration

  • Market Overview
  • Oral Route (PO)
  • Intranasal Route (NAS)
  • Subcutaneous Route (Subcut)
  • Intramuscular Route (IM)

Vaccines Market by End User

  • Market Overview
  • Adult Vaccines
  • Pediatric Vaccines

Vaccines Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • GSK Plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Emergent (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Services, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK-Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Serum Institute of India Pvt., Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bavarian Nordic (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mitsubishi Tanabe Pharma Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Daiichi Sankyo Company, Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Panacea Biotec (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biological E Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bharat Biotech (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novavax (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Inovio Pharmaceuticals (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sinovac (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Incepta Pharmaceuticals Ltd. (Bangladesh)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Valneva SE (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • VBI Vaccine Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio Farma (Indonesia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Microgen (Russia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ZHI FEI Biological (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Indian Immunologicals Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments